Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
暂无分享,去创建一个
Bruce Montgomery | Javed Siddiqui | Walter M Stadler | Arul M Chinnaiyan | David C. Smith | Rohit Mehra | Xuhong Cao | A. Chinnaiyan | K. Cooney | S. Tomlins | R. Mehra | Xuhong Cao | F. Feng | E. Antonarakis | D. Robinson | Y. Whang | J. Siddiqui | P. Corn | K. Knudsen | W. Stadler | C. Albany | Yi-Mi Wu | R. Lonigro | L. Kunju | M. Hussain | B. Montgomery | M. Stein | David C Smith | Maha Hussain | Kathleen A Cooney | Yi-Mi Wu | Robert J Lonigro | Scott A Tomlins | Felix Y Feng | Paul G Corn | Karen E Knudsen | Young E Whang | Emmanuel S Antonarakis | P. Twardowski | Lakshmi P Kunju | Dan Robinson | Mark N Stein | Costantine Albany | Daniel H Shevrin | Stephanie Daignault-Newton | Przemyslaw W Twardowski | Megan V Caram | D. Shevrin | Megan E V Caram | S. Daignault-Newton | M. Caram | Megan E. V. Caram | Xuhong Cao
[1] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[2] A. Chinnaiyan,et al. Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate Cancer , 2014, Applied immunohistochemistry & molecular morphology : AIMM.
[3] Sarat Chandarlapaty,et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.
[4] Shunyou Wang,et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.
[5] D. Gioeli,et al. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. , 2014, Endocrine-related cancer.
[6] K. Ikai,et al. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. , 1981, Cancer letters.
[7] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[8] R A Irvine,et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. , 2000, Cancer research.
[9] Eric F. Johnson,et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.
[10] M. Nykter,et al. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. , 2017, European urology.
[11] Boris Freidlin,et al. Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.
[12] V. Arora,et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.
[13] Kathleen R. Cho,et al. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. , 2015, Cancer research.
[14] A. Chinnaiyan,et al. Dual roles of PARP-1 promote cancer growth and progression. , 2012, Cancer discovery.
[15] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[16] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[17] K. Knudsen,et al. Linking DNA Damage and Hormone Signaling Pathways in Cancer , 2016, Trends in Endocrinology & Metabolism.
[18] T. Taniguchi,et al. Enhanced expression of poly(ADP‐ribose) synthetase gene in malignant lymphoma , 1991, American journal of hematology.
[19] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[20] Joshua M. Korn,et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.
[21] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[22] Martin J. Aryee,et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.
[23] Wei Yan,et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.
[24] H. Hieronymus,et al. Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.
[25] P. Nelson,et al. Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.
[26] F. Feng,et al. A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.
[27] I. Verma,et al. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] F. Hamdy,et al. Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair , 2015, Science Translational Medicine.
[29] O. Hayaishi,et al. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. , 1983, Cancer research.
[30] P. Ellis,et al. ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors , 2009, Clinical Cancer Research.
[31] T. Helleday,et al. Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer , 2013, Clinical Cancer Research.
[32] D. Dearnaley,et al. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate , 2015, European urology.
[33] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[34] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[35] A. Chinnaiyan,et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. , 2012, Archives of pathology & laboratory medicine.
[36] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[37] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.